



Journal home page: <http://www.journalijar.com>

INTERNATIONAL JOURNAL  
OF INNOVATIVE AND APPLIED RESEARCH

## RESEARCH ARTICLE

Article DOI:10.58538/IJAR/2075

DOI URL: <http://dx.doi.org/10.58538/IJAR2075>

### Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup> and Festus Uchechukwu Onuigwe<sup>3</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda.

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda.

<sup>3</sup>Haematology Department, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.

#### Manuscript Info

##### Manuscript History

Received: 15 December 2023

Final Accepted: 11 January 2024

Published: January 2024

##### Keywords:

Platelets, HIV, Modulation,  
Pathogenesis, Immune Response,  
Viral Infection

#### Abstract

Platelets, conventionally recognized for their pivotal roles in hemostasis and thrombosis, have emerged as multifunctional players in immune responses. In the context of Human Immunodeficiency Virus (HIV) infection, platelets exhibit intricate interactions influencing viral pathogenesis, immune activation, and disease progression. This review aims to provide an in-depth analysis of the diverse roles played by platelets in modulating HIV infection, shedding light on their impact on viral dynamics, immune responses, and associated pathophysiological processes. The paper addresses platelet-driven alterations in coagulation pathways and endothelial function in the context of HIV, emphasizing their role in HIV-associated coagulopathies, endothelial activation, and consequent vascular dysfunction. Additionally, the involvement of platelets in the development of HIV-associated comorbidities such as cardiovascular complications, neurocognitive impairment, and systemic inflammation is discussed, delineating platelet-driven mechanisms contributing to the pathogenesis of these conditions and their implications for disease outcomes. In conclusion, the multifaceted roles of platelets in HIV infection underscore their significance beyond hemostasis, offering potential insights into therapeutic avenues and highlighting the need for further investigations to decode the complexity of platelet-driven modulation of HIV infection.

.....  
*\*Corresponding Author: - Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda*  
.....

## Introduction

Human Immunodeficiency Virus (HIV) infection continues to pose a global health challenge, marked by its complex pathogenesis and diverse clinical manifestations. Amidst efforts to comprehend the intricate mechanisms of viral pathogenesis and host responses, emerging evidence has unveiled the integral role of platelets—traditionally known for their hemostatic functions—in influencing HIV infection dynamics and disease progression [1-11]. Historically perceived as blood components crucial for clotting and wound healing, platelets have now garnered attention for their multifaceted involvement in immune responses and inflammatory processes. In the context of HIV infection, platelets exhibit a spectrum of functionalities transcending their conventional roles, participating in a complex interplay with the virus, immune cells, and endothelial components, thereby shaping the course of infection and associated pathologies [12-27].

This paper aims to explore the burgeoning field of platelet-driven modulation of HIV infection, unraveling the diverse mechanisms underlying platelet-virus interactions and their implications for disease pathogenesis. By delving into the intricate interplay between platelets and HIV, this review endeavors to elucidate the multifunctional roles of platelets beyond hemostasis, emphasizing their contributions to viral dynamics, immune activation, and associated pathophysiological processes.

## Platelet-Virus Interactions

Platelets, conventionally recognized for their crucial roles in hemostasis, have emerged as pivotal players in the interplay with Human Immunodeficiency Virus (HIV), exhibiting dynamic interactions that influence viral pathogenesis and disease progression. Understanding the direct interactions between platelets and HIV offers insights into viral dissemination, immune activation, and potential therapeutic avenues [28-37]. HIV exhibits a complex interaction with platelets upon entering the bloodstream. Several studies have demonstrated the ability of platelets to capture and sequester HIV particles through interactions with specific receptors expressed on their surface, including C-type lectin receptors and integrins. This interaction facilitates the binding and internalization of viral particles, potentially affecting their dissemination and distribution within the host [38-47].

Platelets, being mobile blood elements, contribute to the transport and dissemination of HIV within the circulation. Through the formation of platelet-virus complexes, platelets might serve as carriers for HIV, shielding the virus from immune surveillance and potentially aiding in viral dissemination to distant sites, including endothelial surfaces and immune cells [48-58]. The influence of platelet-virus interactions on viral infectivity remains an area of active research. Some evidence suggests that platelet-virus complexes might modulate viral infectivity by

potentially promoting viral internalization into target cells or impacting viral entry pathways, though the precise mechanisms require further elucidation. Additionally, these interactions might influence the establishment of viral reservoirs, affecting the persistence of HIV within the host [59-63].

Platelet-virus interactions extend beyond direct viral capture and dissemination, influencing immune responses during HIV infection. Platelets possess immunomodulatory properties, capable of altering immune cell function and cytokine release. This interaction might contribute to shaping the immune milieu, impacting the balance between viral control and immune activation in HIV-infected individuals [64-73]. Understanding the mechanisms governing platelet-virus interactions holds therapeutic potential. Targeting specific platelet receptors or pathways involved in viral capture and dissemination might offer novel strategies to intervene in viral dissemination or modulate immune responses, potentially impacting disease progression and outcomes.

### **Platelet-Mediated Immune Responses**

In addition to their traditional role in hemostasis, platelets play an integral role in immune regulation and inflammatory processes, exerting multifaceted effects on immune cells and cytokine networks. During Human Immunodeficiency Virus (HIV) infection, platelets exhibit immunomodulatory functions that influence immune cell activation, cytokine release, and overall immune responses, thereby contributing to the dynamic host-virus interplay. Platelets possess the capacity to interact with various immune cells, including monocytes, macrophages, T cells, and dendritic cells, via direct cellular contact or by releasing bioactive molecules [74]. Upon activation, platelets express surface ligands, such as P-selectin and CD40L, capable of binding to immune cell receptors, thereby modulating their activation state and influencing immune responses.

Platelets can secrete a wide array of cytokines, chemokines, and inflammatory mediators upon activation. During HIV infection, platelet-derived factors such as platelet factor 4 (PF4), RANTES, and thromboxane A2 (TXA2) contribute to the local immune milieu, influencing immune cell recruitment, activation, and function within HIV-infected tissues [75]. In HIV infection, platelets participate in the intricate crosstalk between coagulation and inflammation. Platelet activation triggers the release of pro-inflammatory mediators, fostering a procoagulant state. This platelet-driven procoagulant environment may exacerbate inflammation, contributing to immune dysregulation and endothelial dysfunction observed in HIV-infected individuals.

Platelets have been implicated in modulating antiviral immune responses against HIV. Their interactions with immune cells and release of immune mediators can influence the balance between antiviral immune defense mechanisms and viral persistence, potentially impacting viral control and disease progression [76]. Understanding platelet-mediated immune responses in HIV offers potential therapeutic avenues. Targeting platelet-immune cell interactions or inhibiting platelet-derived inflammatory mediators may serve as strategies to modulate immune activation, potentially balancing immune responses and aiding in viral control without excessive inflammation.

## **Role of Platelets in Coagulopathy and Endothelial Dysfunction**

Platelets, beyond their traditional hemostatic functions, significantly contribute to the intricate balance between coagulation and inflammation. In the context of Human Immunodeficiency Virus (HIV) infection, platelets play a pivotal role in the development of coagulopathy and endothelial dysfunction, contributing to vascular complications observed in HIV-infected individuals. HIV infection triggers systemic immune activation and chronic inflammation, contributing to platelet activation. Activated platelets release procoagulant factors, such as thromboxane A<sub>2</sub> (TXA<sub>2</sub>), platelet factor 4 (PF4), and von Willebrand factor (vWF), fostering a prothrombotic state. This hypercoagulable environment contributes to increased thrombotic events and microvascular complications observed in HIV-associated coagulopathies [74].

Platelet activation during HIV infection also contributes to endothelial dysfunction. Activated platelets interact with the endothelium, releasing vasoactive substances and proinflammatory mediators, altering endothelial integrity and function. This disruption of endothelial homeostasis contributes to vascular inflammation, impaired vasodilation, and heightened vascular permeability, exacerbating cardiovascular complications and microvascular pathologies in HIV-infected individuals [75]. The interaction between activated platelets and the endothelium plays a critical role in HIV-related vascular injury. Platelets adhering to the damaged endothelium release factors that further perpetuate endothelial activation and dysfunction, leading to a vicious cycle of vascular injury, inflammation, and thrombotic events in HIV-associated vasculopathy. The interplay between platelets, coagulation pathways, and endothelial dysfunction contributes significantly to the increased risk of cardiovascular events, such as myocardial infarction and stroke, observed in HIV-infected individuals. Moreover, microvascular complications, including HIV-associated thrombotic microangiopathy, are partly attributed to platelet-mediated endothelial injury and prothrombotic states.

## **Platelets and HIV-Associated Comorbidities**

Human Immunodeficiency Virus (HIV) infection is associated with a spectrum of comorbidities, where platelets, beyond their traditional hemostatic roles, contribute to the pathophysiological processes underlying these conditions. Platelets play diverse roles in HIV-associated comorbidities, including cardiovascular complications, neurocognitive impairment, and systemic inflammation, among others.

Platelets contribute significantly to the development of cardiovascular complications in HIV-infected individuals. Chronic immune activation and inflammatory responses lead to platelet activation and endothelial dysfunction, promoting atherosclerosis, myocardial infarction, and other cardiovascular events. Platelet-mediated alterations in coagulation pathways contribute to an increased risk of thrombotic events in HIV-related cardiovascular diseases [74]. HIV-associated neurocognitive disorders (HAND) are prevalent in infected individuals. Platelet activation and subsequent release of inflammatory mediators contribute to neuroinflammation and neurovascular injury, potentially exacerbating cognitive impairment. Platelet-mediated endothelial dysfunction may also play a role in the pathogenesis of HIV-associated neurocognitive impairment [77].

Persistent systemic inflammation characterizes HIV infection and is associated with platelet activation. Activated platelets release inflammatory mediators that contribute to systemic inflammation, fostering a proinflammatory environment that exacerbates immune dysregulation and contributes to the progression of HIV disease and associated comorbidities. HIV-related microvascular complications, such as thrombotic microangiopathy, are influenced by platelet activation and endothelial dysfunction. Platelet-driven alterations in coagulation pathways and endothelial injury contribute to microvascular pathologies observed in HIV-infected individuals, potentially leading to organ-specific complications.

### **Clinical Implications and Therapeutic Prospects**

The intricate involvement of platelets in the pathophysiology of Human Immunodeficiency Virus (HIV) infection presents various clinical implications and offers promising therapeutic avenues. Platelet activation markers, such as platelet factor 4 (PF4) and soluble P-selectin, serve as potential biomarkers reflecting ongoing immune activation and endothelial dysfunction in HIV-infected individuals. Elevated levels of these markers correlate with disease severity and may aid in disease monitoring and prognostication [78]. Identifying HIV-infected individuals at higher risk for cardiovascular complications or thrombotic events based on platelet activation status may facilitate targeted preventive strategies. Early identification of individuals with heightened platelet activation profiles could prompt interventions to mitigate cardiovascular risks, potentially improving patient outcomes.

Antiplatelet agents, such as aspirin or P2Y<sub>12</sub> receptor antagonists, traditionally used in cardiovascular disease management, might find a role as adjunctive therapies in HIV care. These agents, by inhibiting platelet activation, could potentially mitigate HIV-related thrombotic complications and endothelial dysfunction, warranting further investigation in clinical trials [78]. Therapeutic strategies focusing on preserving endothelial function could indirectly impact platelet activation and thrombotic risks in HIV-infected individuals. Endothelial-targeted therapies, including angiotensin-converting enzyme (ACE) inhibitors or statins, may ameliorate endothelial dysfunction, potentially influencing platelet-endothelial interactions and vascular complications.

Effective antiretroviral therapy (ART) remains the cornerstone of HIV management. Achieving and maintaining viral suppression through adherence to ART has shown to reduce chronic immune activation and platelet activation, potentially mitigating HIV-related complications.

### **Conclusion**

The multifaceted roles of platelets in Human Immunodeficiency Virus (HIV) infection extend far beyond their traditional functions in hemostasis, encompassing pivotal contributions to viral pathogenesis, immune modulation, coagulopathy, endothelial dysfunction, and the development of associated comorbidities. Understanding the intricate interplay between platelets and HIV sheds light on critical mechanisms influencing disease progression and complications in affected individuals. Platelets, activated in response to chronic immune activation and inflammation in HIV infection, contribute significantly to viral dissemination, potentially influencing disease severity and progression. Their ability to interact with immune cells, release inflammatory

mediators, and modulate immune responses shapes the immune milieu, impacting viral control and contributing to systemic inflammation observed in HIV-infected individuals.

Moreover, platelet-mediated coagulopathy and endothelial dysfunction play a crucial role in HIV-associated vascular complications, including cardiovascular events, neurocognitive impairment, and microvascular pathologies. Their involvement in promoting thrombotic events and exacerbating endothelial injury underscores their significance in the pathophysiology of HIV-related comorbidities. The clinical implications of understanding platelet-mediated effects in HIV are substantial, offering avenues for risk stratification, prognostication, and the development of targeted therapeutic interventions. Utilizing platelet activation markers as diagnostic and prognostic indicators, exploring antiplatelet agents, endothelial-targeted therapies, and optimizing adherence to antiretroviral therapy (ART) hold promise in managing HIV-associated complications and improving patient outcomes. The comprehensive exploration of platelet involvement in HIV infection unravels intricate mechanisms underlying disease pathogenesis and complications. Leveraging these insights for targeted therapeutic strategies and clinical management may pave the way for more effective approaches to mitigate the impact of HIV-related complications, thereby improving the quality of life and outcomes for affected individuals.

## References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-8. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38. DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5. DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)

8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129.[links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.21960/2022.5.6.129).
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-9.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-9.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International.* 2020;32(22):101-9.
12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation.* 2016; 5:464-471.[links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.21960/2016.5.464-471).
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences.* 2015;4(4):911-6.[https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-5.[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.21960/2017.12.4.70-5)
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-9.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30.[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.21960/2016.5.1.24-30).
18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130.[links/645a166f5762c95ac3817d32/Clinical-characteristics-](https://doi.org/10.21960/2022.5.6.130)

- [of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](#).
19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.[https://www.academia.edu/download/38320159/Obeagu Emmanuel Ifeanyi3 et al IJCRAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al_IJCRAR.pdf).
  20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.<links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf>
  21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: <10.22192/ijcrms.2017.03.02.005>
  22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
  23. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.<links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf>.
  24. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-34.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
  25. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34.
  26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
  27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137.<links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf>.
  28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-42.DOI: <10.22192/ijarbs.2023.10.09.015> <links/6516faa61e2386049de5e828/A-Review-of->



- [knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](#)
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-34. DOI: [10.22192/ijarbs.2023.10.09.014](#) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](#).
  30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-4. DOI: [10.22192/ijcrms.2017.03.05.014](#) [https://www.academia.edu/download/54317126/Haematological\\_indices\\_of\\_malaria\\_patients\\_coinfected\\_with\\_HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
  31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
  32. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
  33. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-83. DOI: [DOI: 10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](#).
  34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
  35. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-11. <http://research.sdpublishers.net/id/eprint/2819/>.
  36. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases.* 2022;10(4):1-7.
  37. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International.* 2021;33(57A):360-8.
  38. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH

- HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
40. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023;10(8): 564-568
41. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatananya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjpr.in/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
42. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-9.
43. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretroviral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8. DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.com/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
44. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13. DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002)  
[links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
45. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.[links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
46. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-10.[https://www.academia.edu/download/38320134/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
47. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
48. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJ RMS). 2023;3(2):28-31.

49. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
50. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-9.
51. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci*. 2014; 5:825-30.
53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-9.
54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-1.
56. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanne CA, Nwanjo HU, Amadike JN, Eemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-71.
57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
58. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-8.
59. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-6.
60. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
61. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-5.

62. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-9.
63. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
64. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
65. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
66. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
67. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
68. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
69. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.
71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res*. 2023;10(10):56-62.
72. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
73. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
74. Ribeiro LS, Migliari Branco L, Franklin BS. Regulation of innate immune responses by platelets. *Frontiers in immunology*. 2019; 10:1320.

75. Hottz ED, Bozza FA, Bozza PT. Platelets in immune response to virus and immunopathology of viral infections. *Frontiers in medicine*. 2018; 5:121.
76. Hottz ED, Bozza FA, Bozza PT. Platelets in immune response to virus and immunopathology of viral infections. *Frontiers in medicine*. 2018; 5:121.
77. Daniel Elbirt M, Mahlab-Guri K, Bazalel-Rosenberg S, Attali M, Asher I. HIV-associated neurocognitive disorders (HAND). *Isr. Med. Assoc. J.* 2015; 17:54.
78. Baidildinova G, Nagy M, Jurk K, Wild PS, Ten Cate H, Van der Meijden PE. Soluble platelet release factors as biomarkers for cardiovascular disease. *Frontiers in cardiovascular medicine*. 2021; 8:684920.
79. Nicolas J, Razuk V, Giustino G, Mehran R. Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. *Future Cardiology*. 2021;17(3):521-34.